Irinotecan as palliative chemotherapy for metastatic colorectal cancer: Evolving tactics following initial treatment

International Journal of Colorectal Disease

Volumn 24, Issue 6, 2009, Pages 605-612

  Mitry, Emmanuel ^a   Liévre, Astrid ^b   Bachet, Jean Baptiste ^a   Rougier, Philippe ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSERM   (France)

Author keywords

Bevacizumab; Capecitabine; Combination treatment; FOLFIRI; FOLFOX; Targeted agents

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; STEROID; VASCULOTROPIN;

BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; INJECTION SITE REACTION; INOPERABLE CANCER; LIVER METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; SALVAGE THERAPY; SKIN TOXICITY; STOMACH CANCER; SURVIVAL TIME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE;

EID: 67349210669     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0672-8     Document Type: Review

References (64)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
2. Europe against colorectal cancer. Declaration of Brussels, May 9, 2007. Available via http://www.future-health-2007.com Accessed 14 Aug 2008
3. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society 2008. Available via http://www.cancer.org/ downloads/STT/2008CAFFfinalsecured.pdf Accessed 14 Aug 2008
4. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282-308
5. Massacesi C, Pistilli B, Valeri M et al (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25:140-148
6. Massacesi C, Norman A, Price T, Hill M, Ross P, Cunningham D (2000) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36:2044-2052
7. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061
8. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237
9. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214
10. Masi G, Marcucci L, Loupakis F et al (2006) First-line 5-fluorouracil/ folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 17:1249-1254
11. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676
12. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
13. Grothey A, Marshall JL (2007) Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology (Williston Park) 21:553-564
14. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
15. Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 26:689-690
16. Chau I, Norman AR, Cunningham D et al (2004) Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91:1453-1458
17. Lal R, Dickson J, Cunningham D et al (2004) A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 22:3023-3031
18. Van Cutsem E, Dirix L, Van Laethem J-L et al (2005) Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: Results from a multinational, randomised phase II study. Br J Cancer 92:1055-1062
19. Bamias A, Papamichael D, Syrigos K, Pavlidis N (2003) Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother 15:275-281
20. Scheithauer W, Kornek GV, Brugger S et al (2002) Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 20:60-68
21. Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA (2002) Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216-1220
22. Rougier P, Lepille D, Bennouna J et al (2002) Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 13:1558-1567
23. Twelves C (2002) Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 16(12 Suppl No 14):23-26
24. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292
25. Scheithauer W, McKendrick J, Begbie S et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743
26. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106
27. Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142
28. Hoff PM, Pazdur R, Lassere Y et al (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22:2078-2083
29. Pfeiffer P, Sorbye H, Ehrsson H et al (2006) Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 17:252-258
30. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786
31. Hofheinz RD, Gnad-Vogt U, Wein A et al (2005) Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: A phase II study. Anticancer Drugs 16:39-45
32. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544
33. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ (2007) Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol. 13:6231-6235
34. Lièvre A, Samalin E, Senesse P (2007) Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as second-line, third-line or later treatment in metastatic colorectal cancer (MCRC) patients. J Clin Oncol 25: Abstract 14558
35. Lenz HJ, Van CE, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-4921
36. Jonker DJ, O'Callaghan CJ (2007) Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
37. Adam R, Aloia T, Levi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593-4602
38. Lim RS, Sun Y, Im SA et al (2007) Cetuximab in combination with irinotecan in the treatment of patients (pts) with metastatic colorectal carcinoma (mCRC) refractory to irinotecan: Preliminary data from the ELSIE study. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, Orlando, FL. Abstract 371
39. Fagnani D, Bertolini A, Menatti E et al (2007) Cetuximab and irinotecan (CPT11) salvage treatment for colorectal cancer (CRC) in progression after two or more chemotherapy (CT) lines: The POLONORD Group experience. J Clin Oncol 25: Abstract 14575
40. Bouchahda M, Macarulla T, Spano JP et al (2007) Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. J Clin Oncol 25: Abstract 14528
41. Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. Br J Cancer 94:792-797
42. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 25:4557-4561
43. Punt CJ, Tol J, Rodenburg CJ et al (2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(suppl): Abstract LBA4011
44. Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379
45. Van Cutsem E, Lang I, D'haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26: Abstract 2
46. Folprecht G, Lutz MP, Schöffski P et al (2005) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456
47. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
48. Hecht JR, Mitchell E, Chidiac T et al (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). American Society of Clinical Oncology Gastrointestinal Symposium; June 25-27, Orlando, Florida. Abstract 273
49. Mitchell EP, LaCouture M, Shearer H et al (2008) A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving 2nd line FOLFIRI or irinotecan-only chemotherapy (CT) with panitumumab (pmab): Early analysis. American Society of Clinical Oncology Gastrointestinal Symposium; June 25-27 Orlando, Florida. Abstract 462
50. Markman M (2008) Combination versus sequential chemotherapy administration: Is it time for a reevaluation of the issue? Curr Oncol Rep 10:93-94
51. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis. Lancet Oncol 8:898-911
52. Hobday TJ, Goldberg RM (2002) Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer 2:161-169
53. Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453-1459
54. Seymour MT, Maughan TS, Ledermann JA et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152
55. Bouche O, Castaing M, Etienne PL et al (2007) Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. J Clin Oncol 25: Abstract 4069
56. Souglakos J, Androulakis N, Syrigos K et al (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798-805
57. Braun MS, Quirke P, Seymour MT (2007) Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Rev Anticancer Ther 7:489-501
58. Casado E, De CJ, Belda-Iniesta C et al (2007) Molecular markers in colorectal cancer: Genetic bases for a customised treatment. Clin Transl Oncol 9:549-554
59. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113-130
60. Shankaran V, Wisinski KB, Mulcahy MF, Benson AB (2008) The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 12:87-98
61. Wright CM, Dent OF, Barker M et al (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197-1202
62. Miller CR, McLeod HL (2007) Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 5:9-14
63. Brueckl WM, Moesch C, Brabletz T et al (2003) Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23:1773-1777
64. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257